CCFP
RMD icon

Charles Carroll Financial Partners’s ResMed RMD Stock Holding History

Charles Carroll Financial Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,500
Closed -$734K – 46
2022
Q2 		$734K Buy
+3,500
New +$745K 0.96% 22

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Charles Carroll Financial Partners's RMD Position: Q3 2022 in Review

Charles Carroll Financial Partners sold out of ResMed (RMD) in Q3 2022, closing a stake of 3,500 shares — an estimated $734K sold.

Charles Carroll Financial Partners first reported a position in RMD in Q2 2022 and held it in 1 quarter. The position peaked at $734K in Q2 2022. 668 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

  • Charles Carroll Financial Partners reported no remaining ResMed position as of Q3 2022 after selling out during the quarter.
  • Charles Carroll Financial Partners sold 3,500 ResMed shares in Q3 2022, an estimated $734K.
  • Charles Carroll Financial Partners first reported a position in ResMed in Q2 2022 and held it in 1 quarter.
  • Charles Carroll Financial Partners's ResMed position peaked at $734K in Q2 2022.
  • 668 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on Charles Carroll Financial Partners's 13F filing for Q3 2022, filed 14 Nov 2022.